04 September 2010
Keywords: Phytopharm, Cogane, Parkinson's, Research
Article | 15 October 2009
UK-based Phytopharm saw its share price rocket almost 350% to 26.75 pence, after the company announced encouraging results from two studies of its Cogane (PYM50028), a novel non-peptide, orally bioavailable neurotrophic factor inducer treatment for Parkinson's disease.
A non-clinical efficacy study showed oral administration of Cogane over 18 weeks significantly reduced parkinsonian disability by 43% in non-human primates. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.